Immunome Inc. (IMNM) stock
IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$18.77+0.07 (+0.37%)
Close on Nov 13, 2026Market cap $2.13BP/E –Yield –
Immunome profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Immunome's profit margin for the twelve months ending Mar 31, 2026 was -5593.8%. For fiscal 2025 it was -3060.0%, against -3240.4% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -3060.0% | +180.4 |
| FY2024 | Dec 31, 2024 | -3240.4% | −2478.5 |
| FY2023 | Dec 31, 2023 | -761.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | -1080.9% | +447.1 |
| Q1 FY2025 | Mar 31, 2025 | -1423.1% | +11161.2 |
| Q4 FY2024 | Dec 31, 2024 | -2930.9% | −509.8 |
| Q3 FY2024 | Sep 30, 2024 | -1618.6% | −1496.7 |
| Q2 FY2024 | Jun 30, 2024 | -1528.0% | −1397.6 |
| Q1 FY2024 | Mar 31, 2024 | -12584.3% | −12403.6 |
| Q4 FY2023 | Dec 31, 2023 | -2421.2% | – |
| Q3 FY2023 | Sep 30, 2023 | -121.9% | – |
| Q2 FY2023 | Jun 30, 2023 | -130.4% | – |
| Q1 FY2023 | Mar 31, 2023 | -180.6% | – |
See a number that looks wrong?